Company · XERS · CIK 1867096

Xeris Biopharma Holdings, Inc. (XERS) SEC filings and CIK.

XERS’s SEC Central Index Key (CIK) is 0001867096, or 1867096 without leading zeros. The SEC’s ticker file lists it as Xeris Biopharma Holdings, Inc..

Ticker
XERS
CIK
0001867096
Other tickers
None
Insider transactions, Q3 2026
14

Insider trading

In Q3 2026, insiders at Xeris Biopharma Holdings, Inc. reported 14 non-derivative transactions on 14 Forms 3, 4 and 5, including 0 open-market purchases and 11 sales. See every XERS insider transaction →

Recent filings we observed

From our record of EDGAR’s latest-filings feed and sampled daily indexes. Not a complete filing history; use the filings API for that.
FiledFormAccession
2026-11-0640001867096-26-000119
2026-10-30SCHEDULE 13G/A0002100119-26-001642

Get XERS SEC data through the API

Filing history
curl "https://sec-api.dev/api/v1/filings?cik=1867096&limit=10" \
  -H "Authorization: Bearer $SEC_API_KEY"
Company profile
curl "https://sec-api.dev/api/v1/companies/1867096" \
  -H "Authorization: Bearer $SEC_API_KEY"
Reported XBRL facts
curl "https://sec-api.dev/api/v1/facts/1867096?taxonomy=us-gaap&concept=Revenues&limit=10" \
  -H "Authorization: Bearer $SEC_API_KEY"

Ticker to CIK API · SEC filings API · Xeris Biopharma Holdings, Inc. on SEC.gov

Questions

What is XERS’s CIK number?

XERS’s SEC Central Index Key (CIK) is 0001867096, or 1867096 without leading zeros. The SEC’s ticker file lists it as Xeris Biopharma Holdings, Inc..

How do I find Xeris Biopharma Holdings, Inc.’s 10-K?

Request /api/v1/filings?cik=1867096&form=10-K, or open the company’s EDGAR page and filter by 10-K. Foreign issuers file 20-F or 40-F instead.

Ticker and CIK: SEC company_tickers.json, cached 2026-11-02. Tickers can move between entities; the CIK identifies the filer.

Plain-text version for agents and LLMs: /companies/xers.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.